bio-techne® RDSYSTEMS

Mouse VEGFR1/Flt-1 Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: AF471

| DESCRIPTION | |
|--------------------|---|
| Species Reactivity | Mouse |
| Specificity | Detects mouse VEGFR1/Flt-1 in ELISAs and Western blots. |
| Source | Polyclonal Goat IgG |
| Purification | Antigen Affinity-purified |
| Immunogen | Mouse myeloma cell line NS0-derived recombinant mouse VEGFR1/FIt-1 Ser27-Glu759 Accession # P35969 |
| Endotoxin Level | <0.10 EU per 1 µg of the antibody by the LAL method. |
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 μm filtered solution in PBS. |

APPLICATIONS

DATA

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website. Recommended Sample Concentration Western Blot 0.1 µg/mL Recombinant Mouse VEGFR1/FIt-1 Fc Chimera (Catalog # 471-F1) Mouse VEGFR1/Flt-1 Sandwich Immunoassay Reagent ELISA Capture 0.2-0.8 µg/mL Mouse VEGFR1/Flt-1 Antibody (Catalog # AF471) 0.1-0.4 µg/mL Mouse VEGFR1/FIt-1 Biotinylated Antibody (Catalog # BAF471) ELISA Detection Standard Recombinant Mouse VEGFR1/Flt-1 Fc Chimera (Catalog # 471-F1) CyTOF-ready Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation Neutralization Measured by its ability to neutralize VEGF₁₆₄-induced proliferation in HUVEC human umbilical vein endothelial cells. The Neutralization Dose (ND $_{50}$) is typically 2-8 μ g/mL in the presence of 5 ng/mL Recombinant Mouse VEGF 164.



| Reconstitution | Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration. |
|---------------------|--|
| Shipping | Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| | 12 months from date of receipt, -20 to -70 °C as supplied. |
| | 1 month, 2 to 8 °C under sterile conditions after reconstitution. |
| | 6 months, -20 to -70 °C under sterile conditions after reconstitution. |

Rev. 6/17/2025 Page 1 of 2

Bio-Techne®

Global | bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL: 1.612.379.2956 USA | TEL: 800.343.7475 Canada | TEL: 855.668.8722 Europe | Middle East | Africa TEL: +44.0.1235.529449 China | info.cn@bio-techne.com TEL: 400.821.3475



Mouse VEGFR1/Flt-1 Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: AF471

BACKGROUND

VEGFR1 is one of the five receptor tyrosine kinases (RTKs) (VEGFR1, KDR/Flk-1, Flt-4, Tie-1, and Tek/Tie-2) whose expression is almost exclusively restricted to the endothelial cells. Tie-1 and tek/tie-2 define a new class of RTKs containing two immunoglobulin-like domains, three EGF homology domains and three fibronectin type III domains in their extracellular regions. VEGFR1/Flt-1, VEGFR2/KDR/Flk-1, VEGFR3/Flt-4 are members of the class III subfamily of RTKs containing seven immunoglobulin-like repeats in their extracellular domains. All five RTKs are likely to play central roles in vasculogenesis and angiogenesis.

Full length mouse VEGFR1 mRNA encodes a 1333 amino acid (aa) residue precursor with a predicted 22 aa residue signal peptide. Mature VEGFR1 is composed of a 737 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 552 aa residue cytoplasmic domain. As a result of alternative splicing of the mRNA, a cDNA encoding a truncated form of VEGFR1, lacking the seventh immunoglobulin-like domain, the transmembrane and intracellular domains, has been cloned. The recombinant soluble VEGFR1/Fc chimera binds VEGF and PIGF with high affinity and is a potent VEGF antagonist.

References:

- 1. He, Y. et al. (1999) Molecular Endocrinology 13:537.
- 2. Ferrara, N. and T. Davis-Smyth (1997) Endocrine Reviews 8:4.